Takeda to Sell Consumer Health Care Business for 2.3 Billion, Focus on Innovative Medicines

Takeda has entered into an agreement to divest Takeda Consumer Healthcare Company (TCHC), a wholly-owned subsidiary of Takeda focused on the consumer health care market primarily in Japan, to a company controlled by funds managed by The Blackstone Group for a total value of 2.3 billion USD. The transaction is expected to close by March 31, 2021, subject to customary legal and regulatory closing conditions. The portfolio to be divested to Blackstone includes a variety of over-the-counter medicines and health products.

Takeda, which started TCHC as a separate business in April 2017 to further develop the consumer health care business in Japan, is now focused on highly innovative medicines across its five key business areas – Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience – and working to address significant unmet patient needs in these fields. (Source: Takeda Website, 24 August, 2020)